ERBB2 and colorectal carcinoma: Two of the first anti-HER2 phase II trials involving patients with treatment-naive or pre-treated trials in CRC evaluated trastuzumab, in combination with chemotherapy, obtaining some degree of ORR; however, both were prematurely closed (the first due to low efficacy and the second due to low patient accrual) [67,68].